<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR201.html">Part 201
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 201.66  Format and content requirements for over-the-counter
                            </h3>
                            <p class="depth1"><em>(a)</em> Scope. This section sets forth the content and format  requirements for the labeling of all OTC drug products. Where an OTC  drug product is the subject of an applicable monograph or regulation  that contains content and format requirements that conflict with this  section, the content and format requirements in this section must be  followed unless otherwise specifically provided in the applicable  monograph or regulation.</p><p class="depth1"><em>(b)</em> Definitions. The following definitions apply to this section:</p><p class="depth2"><em>(1)</em> Act means the Federal Food, Drug, and Cosmetic Act (secs. 201 et  seq. (21 U.S.C. 321 et seq.)).</p><p class="depth2"><em>(2)</em> Active ingredient means any component that is intended to  furnish pharmacological activity or other direct effect in the  diagnosis, cure, mitigation, treatment, or prevention of disease, or to  affect the structure or any function of the body of humans. The term  includes those components that may undergo chemical change in the  manufacture of the drug product and be present in the drug product in a  modified form intended to furnish the specified activity or effect.</p><p class="depth2"><em>(3)</em> Approved drug application means a new drug (NDA) or abbreviated  new drug (ANDA) application approved under section 505 of the act (21  U.S.C. 355).</p><p class="depth2"><em>(4)</em> of this section.</p><p class="depth2"><em>(5)</em> Established name of a drug or ingredient thereof means the  applicable official name designated under section 508 of the act (21  U.S.C. 358), or, if there is no designated official name and the drug or  ingredient is recognized in an official compendium, the official title  of the drug or ingredient in such compendium, or, if there is no  designated official name and the drug or ingredient is not recognized in  an official compendium, the common or usual name of the drug or  ingredient.</p><p class="depth2"><em>(6)</em> FDA means the Food and Drug Administration.</p><p class="depth2"><em>(7)</em> Heading means the required statements in quotation marks listed  in paragraphs (c)(2) through (c)(9) of this section, excluding  subheadings (as defined in paragraph (a)(9) of this section).</p><p class="depth2"><em>(8)</em> Inactive ingredient means any component other than an active  ingredient.</p><p class="depth2"><em>(9)</em> Subheading means the required statements in quotation marks  listed in paragraphs (c)(5)(ii) through (c)(5)(vii) of this section.</p><p class="depth2"><em>(10)</em> Drug facts labeling means the title, headings, subheadings, and  information required under or otherwise described in paragraph (c) of  this section.</p><p class="depth2"><em>(11)</em> Title means the heading listed at the top of the required OTC  drug product labeling, as set forth in paragraph (c)(1) of this section.</p><p class="depth2"><em>(12)</em> Total surface area available to bear labeling means all  surfaces of the outside container of the retail package or, if there is  no such outside container, all surfaces of the immediate container or  container wrapper except for the flanges at the tops and bottoms of cans  and the shoulders and necks of bottles and jars.</p><p class="depth1"><em>(c)(9)</em> of this section, in the order listed.</p><p class="depth2"><em>(1)</em> (Title) ``Drug Facts''. If the drug facts labeling appears on  more than one panel, the title ``Drug Facts (continued)'' shall appear  at the top of each subsequent panel containing such information.</p><p class="depth2"><em>(2)</em> ``Active ingredient'' or ``Active ingredients'' ``(in each  [insert the dosage unit stated in the directions for use (e.g., tablet,  5 mL teaspoonful) or in each gram as stated in Sec. Sec. 333.110 and  333.120 of this chapter])'', followed by the established name of each  active ingredient and the quantity of each active ingredient per dosage  unit. Unless otherwise provided in an applicable OTC drug monograph or  approved drug application, products marketed without discrete dosage  units (e.g., topicals) shall state the proportion (rather than the  quantity) of each active ingredient.</p><p class="depth2"><em>(3)</em> ``Purpose'' or ``Purposes'', followed by the general  pharmacological category(ies) or the principal intended action(s) of the  drug or, where the drug consists of more than one ingredient, the  general pharmacological categories or the principal intended actions of  each active ingredient. When an OTC drug monograph contains a statement  of identity, the pharmacological action described in the statement of  identity shall also be stated as the purpose of the active ingredient.</p><p class="depth2"><em>(4)</em> ``Use'' or ``Uses'', followed by the indication(s) for the  specific drug product.</p><p class="depth2"><em>(5)</em> ``Warning'' or ``Warnings'', followed by one or more of the  following, if applicable:</p><p class="depth3"><em>(i)</em> ``For external use only'' [in bold type] for topical drug  products not intended for ingestion, or ``For'' (select one of the  following, as appropriate: ``rectal'' or ``vaginal'') ``use only'' [in  bold type].</p><p class="depth3"><em>(ii)(G)</em> of this section with the appropriate subheadings  highlighted in bold type:</p><p class="depth4"><em>(A)</em> Reye's syndrome warning for drug products containing salicylates  set forth in Sec. 201.314(h)(1). This warning shall follow the  subheading ``Reye's syndrome:''</p><p class="depth4"><em>(B)</em> Allergic reaction and asthma alert warnings. Allergic reaction  warnings set forth in any applicable OTC drug monograph or approved drug  application for any product that requires a separate allergy warning.  This warning shall follow the subheading ``Allergy alert:'' The asthma  alert warning set forth in Sec. Sec. 341.76(c)(5) and 341.76(c)(6) of  this chapter. This warning shall follow the subheading ``Asthma alert:''</p><p class="depth4"><em>(C)</em> Flammability warning, with appropriate flammability signal  word(s) (e.g., Sec. Sec. 341.74(c)(5)(iii), 344.52(c), 358.150(c), and  358.550(c) of this chapter). This warning shall follow a subheading  containing the appropriate flammability signal word(s) described in an  applicable OTC drug monograph or approved drug application.</p><p class="depth4"><em>(D)</em> Water soluble gums warning set forth in Sec. 201.319. This  warning shall follow the subheading ``Choking:''</p><p class="depth4"><em>(E)</em> Liver warning set forth in Sec. 201.326(a)(1)(iii) and/or  stomach bleeding warning set forth in Sec. 201.326(a)(2)(iii). The  liver warning shall follow the subheading ``Liver warning:'' and the  stomach bleeding warning shall follow the subheading ``Stomach bleeding  warning:''</p><p class="depth4"><em>(F)</em> Sore throat warning set forth in Sec. 201.315. This warning  shall follow the subheading ``Sore throat warning:''</p><p class="depth4"><em>(G)</em> Warning for drug products containing sodium phosphates set forth  in Sec. 201.307(b)(2)(i) or (b)(2)(ii). This warning shall follow the  subheading ``Dosage warning:''</p><p class="depth4"><em>(H)</em> Sexually transmitted diseases (STDs) warning for vaginal  contraceptive and spermicide drug products containing nonoxynol 9 set  forth in Sec. 201.325(b)(2). This warning shall follow the subheading  ``Sexually transmitted diseases (STDs) alert:''</p><p class="depth3"><em>(iii)</em> ``Do not use'' [in bold type], followed by all  contraindications for use with the product. These contraindications are  absolute and are intended for situations in which consumers should not  use the product unless a prior diagnosis has been established by a  doctor or for situations in which certain consumers should not use the  product under any circumstances regardless of   whether a doctor or health professional is consulted.</p><p class="depth3"><em>(iv)</em> ``Ask a doctor before use if you have'' [in bold type] or, for  products labeled only for use in children under 12 years of age, ``Ask a  doctor before use if the child has'' [in bold type], followed by all  warnings for persons with certain preexisting conditions (excluding  pregnancy) and all warnings for persons experiencing certain symptoms.  The warnings under this heading are those intended only for situations  in which consumers should not use the product until a doctor is  consulted.</p><p class="depth3"><em>(v)</em> ``Ask a doctor or pharmacist before use if you are'' [in bold  type] or, for products labeled only for use in children under 12 years  of age, ``Ask a doctor or pharmacist before use if the child is'' [in  bold type], followed by all drug-drug and drug-food interaction  warnings.</p><p class="depth3"><em>(vi)</em> ``When using this product'' [in bold type], followed by the  side effects that the consumer may experience, and the substances (e.g.,  alcohol) or activities (e.g., operating machinery, driving a car,  warnings set forth in Sec. 369.21 of this chapter for drugs in  dispensers pressurized by gaseous propellants) to avoid while using the  product.</p><p class="depth3"><em>(vii)</em> ``Stop use and ask a doctor if'' [in bold type], followed by  any signs of toxicity or other reactions that would necessitate  immediately discontinuing use of the product. For all OTC drug products  under an approved drug application whose packaging does not include a  toll-free number through which consumers can report complaints to the  manufacturer or distributor of the drug product, the following text  shall immediately follow the subheading: ``[Bullet] side effects occur.  You may report side effects to FDA at 1-800-FDA-1088.'' The telephone  number must appear in a minimum 6-point bold letter height or type size.</p><p class="depth3"><em>(viii)</em> Any required warnings in an applicable OTC drug monograph,  other OTC drug regulations, or approved drug application that do not fit  within one of the categories listed in paragraphs (c)(5)(i) through  (c)(5)(vii), (c)(5)(ix), and (c)(5)(x) of this section.</p><p class="depth3"><em>(ix)</em> The pregnancy/breast-feeding warning set forth in Sec.  201.63(a); the third trimester warning set forth in Sec. 201.63(e) for  products containing aspirin or carbaspirin calcium; the third trimester  warning set forth in approved drug applications for products containing  ketoprofen, naproxen sodium, and ibuprofen (not intended exclusively for  use in children).</p><p class="depth3"><em>(x)</em> The ``Keep out of reach of children'' warning and the accidental  overdose/ingestion warning set forth in Sec. 330.1(g) of this chapter.</p><p class="depth2"><em>(6)</em> ``Directions'', followed by the directions for use described in  an applicable OTC drug monograph or approved drug application.</p><p class="depth2"><em>(7)</em> ``Other information'', followed by additional information that  is not included under paragraphs (c)(2) through (c)(6), (c)(8), and  (c)(9) of this section, but which is required by or is made optional  under an applicable OTC drug monograph, other OTC drug regulation, or is  included in the labeling of an approved drug application.</p><p class="depth3"><em>(i)</em> Required information about certain ingredients in OTC drug  products (e.g., sodium in Sec. 201.64(b), calcium in Sec. 201.70(b),  magnesium in Sec. 201.71(b), and potassium in Sec. 201.72(b)) shall  appear as follows: ``each (insert appropriate dosage unit) contains:''  [in bold type (insert name(s) of ingredient(s) (in alphabetical order)  and the quantity of each ingredient). This information shall be the  first statement under this heading.</p><p class="depth3"><em>(ii)</em> The phenylalanine/aspartame content required by Sec.  201.21(b), if applicable, shall appear as the next item of information.</p><p class="depth3"><em>(iii)</em> Additional information that is authorized to appear under this  heading shall appear as the next item(s) of information. There is no  required order for this subsequent information.</p><p class="depth2"><em>(8)</em> ``Inactive ingredients'', followed by a listing of the  established name of each inactive ingredient. If the product is an OTC  drug product that is not also a cosmetic product, then the inactive  ingredients shall be listed in alphabetical order. If the product is an  OTC drug product that is also a cosmetic product, then the inactive  ingredients shall be listed as set forth in Sec. 701.3(a) or (f) of  this chapter, the names of cosmetic ingredients shall be determined in  accordance with Sec. 701.3(c) of this chapter, and the provisions in  Sec. 701.3(e), (g), (h), (l), (m), (n), and (o) of this   chapter and Sec. 720.8 of this chapter may also apply, as appropriate.  If there is a difference in the labeling provisions in this Sec. 201.66  and Sec. Sec. 701.3 and 720.8 of this chapter, the labeling provisions  in this Sec. 201.66 shall be used.</p><p class="depth2"><em>(9)</em> ``Questions?'' or ``Questions or comments?'', followed by the  telephone number of a source to answer questions about the product. It  is recommended that the days of the week and times of the day when a  person is available to respond to questions also be included. A graphic  of a telephone or telephone receiver may appear before the heading. The  telephone number must appear in a minimum 6-point bold type.</p><p class="depth1"><em>(d)</em> Format requirements. The title, headings, subheadings, and  information set forth in paragraphs (c)(1) through (c)(9) of this  section shall be presented on OTC drug products in accordance with the  following specifications. In the interest of uniformity of presentation,  FDA strongly reccommends that the Drug Facts labeling be presented using  the graphic specifications set forth in appendix A to part 201.</p><p class="depth2"><em>(1)</em>, (c)(2), and  (c)(4) through (c)(9) of this section shall be left justified.</p><p class="depth2"><em>(2)</em> through (c)(9) of this section shall be  no smaller than 6-point type.</p><p class="depth2"><em>(3)</em> The title, heading, subheadings, and information in paragraphs  (c)(1) through (c)(9) of this section shall be legible and clearly  presented, shall have at least 0.5-point leading (i.e., space between  two lines of text), and shall not have letters that touch. The type  style for the title, headings, subheadings, and all other required  information described in paragraphs (c)(2) through (c)(9) of this  section shall be any single, clear, easy-to-read type style, with no  more than 39 characters per inch. The title and headings shall be in  bold italic, and the subheadings shall be in bold type, except that the  word ``(continued)'' in the title ``Drug Facts (continued)'' shall be  regular type. The type shall be all black or one color printed on a  white or other contrasting background, except that the title and the  headings may be presented in a single, alternative, contrasting color  unless otherwise provided in an approved drug application, OTC drug  monograph (e.g., current requirements for bold print in Sec. Sec.  341.76 and 341.80 of this chapter), or other OTC drug regulation (e.g.,  the requirement for a box and red letters in Sec. 201.308(c)(1)).</p><p class="depth2"><em>(4)</em> through  (c)(7) of this section shall be preceded by a solid square or solid  circle bullet of 5-point type size. Bullets shall be presented in the  same shape and color throughout the labeling. The first bulleted  statement on each horizontal line of text shall be either left justified  or separated from an appropriate heading or subheading by at least two  square ``ems'' (i.e., two squares of the size of the letter ``M''). If  more than one bulleted statement is placed on the same horizontal line,  the end of one bulleted statement shall be separated from the beginning  of the next bulleted statement by at least two square ``ems'' and the  complete additional bulleted statement(s) shall not continue to the next  line of text. Additional bulleted statements appearing on each  subsequent horizontal line of text under a heading or subheading shall  be vertically aligned with the bulleted statements appearing on the  previous line.</p><p class="depth2"><em>(5)</em> The title, headings, subheadings, and information set forth in  paragraphs (c)(1) through (c)(9) of this section may appear on more than  one panel on the outside container of the retail package, or the  immediate container label if there is no outside container or wrapper.  The continuation of the required content and format onto multiple panels  must retain the required order and flow of headings, subheadings, and  information. A visual graphic (e.g., an arrow) shall be used to signal  the continuation of the Drug Facts labeling to the next adjacent panel.</p><p class="depth2"><em>(6)</em> through (c)(9) of  this section may start on the same line as the required headings. None  of the information described in paragraph (c)(5) of this section shall  appear on the same line as the ``Warning'' or ``Warnings'' heading.</p><p class="depth2"><em>(7)</em> Graphical images (e.g., the UPC symbol) and information not  described in paragraphs (c)(1) through (c)(9) of this section shall not  appear in or in any way interrupt the required title, headings,  subheadings, and information in paragraphs (c)(1) through (c)(9) of this  section. Hyphens shall not be used except to punctuate compound words.</p><p class="depth2"><em>(8)</em> The information described in paragraphs (c)(1) through (c)(9) of  this section shall be set off in a box or similar enclosure by the use  of a barline. A distinctive horizontal barline extending to each end of  the ``Drug Facts'' box or similar enclosure shall provide separation  between each of the headings listed in paragraphs (c)(2) through (c)(9)  of this section. When a heading listed in paragraphs (c)(2) through  (c)(9) of this section appears on a subsequent panel immediately after  the ``Drug Facts (continued)'' title, a horizontal hairline shall follow  the title and immediately precede the heading. A horizontal hairline  extending within two spaces on either side of the ``Drug Facts'' box or  similar enclosure shall immediately follow the title and shall  immediately precede each of the subheadings set forth in paragraph  (c)(5) of this section, except the subheadings in paragraphs  (c)(5)(ii)(A) through (c)(5)(ii)(G) of this section.</p><p class="depth2"><em>(9)</em> The information set forth in paragraph (c)(6) of this section  under the heading ``Directions'' shall appear in a table format when  dosage directions are provided for three or more age groups or  populations. The last line of the table may be the horizontal barline  immediately preceding the heading of the next section of the labeling.</p><p class="depth2"><em>(10)(v)</em> of this section. In  determining whether more than 60 percent of the total surface area  available to bear labeling is required, the indications for use listed  under the ``Use(s)'' heading, as set forth in paragraph (c)(4) of this  section, shall be limited to the minimum required uses reflected in the  applicable   monograph, as provided in Sec. 330.1(c)(2) of this chapter.</p><p class="depth3"><em>(i)</em> Paragraphs (d)(1), (d)(5), (d)(6), and (d)(7) of this section  shall apply.</p><p class="depth3"><em>(ii)</em> Paragraph (d)(2) of this section shall apply except that the  letter height or type size for the title ``Drug Facts (continued)''  shall be no smaller than 7-point type and the headings in paragraphs  (c)(2) through (c)(9) of this section shall be the larger of either 7- point or greater type, or 1-point size greater than the point size of  the text.</p><p class="depth3"><em>(iii)</em> Paragraph (d)(3) of this section shall apply except that less  than 0.5-point leading may be used, provided the ascenders and  descenders do not touch.</p><p class="depth3"><em>(iv)</em> Paragraph (d)(4) of this section shall apply except that if  more than one bulleted statement is placed on the same horizontal line,  the additional bulleted statements may continue to the next line of  text, and except that the bullets under each heading or subheading need  not be vertically aligned.</p><p class="depth3"><em>(v)</em> Paragraph (d)(8) of this section shall apply except that the box  or similar enclosure required in paragraph (d)(8) of this section may be  omitted if the Drug Facts labeling is set off from the rest of the  labeling by use of color contrast.</p><p class="depth2"><em>(11)</em></p><p class="depth3"><em>(i)</em> The following labeling outlines the various provisions in  paragraphs (c) and (d) of this section: [GRAPHIC] [TIFF OMITTED] TR17MR99.003</p><p class="depth3"><em>(ii)</em> The following sample label illustrates the provisions in  paragraphs (c) and (d) of this section:   [GRAPHIC] [TIFF OMITTED] TR17MR99.004</p><p class="depth3"><em>(iii)</em> The following sample label illustrates the provisions in  paragraphs (c) and (d) of this section, including paragraph (d)(10) of  this section, which permits modifications for small packages:   [GRAPHIC] [TIFF OMITTED] TR17MR99.005</p><p class="depth3"><em>(iv)</em> The following sample label illustrates the provisions in  paragraphs (c) and (d) of this section for a drug product marketed with  cosmetic claims:   [GRAPHIC] [TIFF OMITTED] TR17MR99.006</p><p class="depth1"><em>(e)</em> Exemptions and deferrals. FDA on its own initiative or in  response to a written request from any manufacturer, packer, or  distributor, may exempt or defer, based on the circumstances presented,  one or more specific requirements set forth in this section on the basis  that the requirement is inapplicable, impracticable, or contrary to  public health or safety. Requests for exemptions shall be submitted in  three copies in the form of an ``Application for Exemption'' to the Food  and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD  20852. The request shall be clearly identified on the envelope as a  ``Request for Exemption from 21 CFR 201.66 (OTC Labeling Format)'' and  shall be directed to Docket No. 98N-0337. A separate request shall be  submitted for each OTC drug product. Sponsors of a product marketed  under an approved drug application shall also submit a single copy of  the exemption request to their application. Decisions on exemptions and  deferrals will be maintained in a permanent file in this docket for  public review. Exemption and deferral requests shall:</p><p class="depth2"><em>(1)</em> Document why a particular requirement is inapplicable,  impracticable, or is contrary to public health or safety; and</p><p class="depth2"><em>(2)</em> Include a representation of the proposed labeling, including any  outserts, panel extensions, or other graphical or packaging techniques  intended to be used with the product.</p><p class="depth1"><em>(f)</em> Interchangeable terms and connecting terms. The terms listed in  Sec. 330.1(i) of this chapter may be used   interchangeably in the labeling of OTC drug products, provided such use  does not alter the meaning of the labeling that has been established and  identified in an applicable OTC drug monograph or by regulation. The  terms listed in Sec. 330.1(j) of this chapter may be deleted from the  labeling of OTC drug products when the labeling is revised to comply  with this section, provided such deletion does not alter the meaning of  the labeling that has been established and identified in an applicable  OTC drug monograph or by regulation. The terms listed in Sec. 330.1(i)  and (j) of this chapter shall not be used to change in any way the  specific title, headings, and subheadings required under paragraphs  (c)(1) through (c)(9) of this section.</p><p class="depth1"><em>(g)</em> Regulatory action. An OTC drug product that is not in compliance  with the format and content requirements in this section is subject to  regulatory action.  [64 FR 13286, Mar. 17, 1999, as amended at 65 FR 8, Jan. 3, 2000; 65 FR  48904, Aug. 10, 2000; 69 FR 13733, Mar. 24, 2004; 72 FR 71785, Dec. 19,  2007; 73 FR 403, Jan. 3, 2008; 74 FR 19407, Apr. 29, 2009; 76 FR 44487,  July 26, 2011]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ❤ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
